The past decade has seen a resurgence in the field of cell and gene therapy, with three treatments being approved by the European Medicines Agency and the US Food and Drug Administration and a flood of candidate therapies
In a recent article in IPT magazine, Synpromics’ founder and Chief Scientific Officer Dr. Michael L Roberts discusses the current obstacles to overcome in optimising gene therapies.
Synpromics Ltd, the leader in gene control, is listed by The Scotsman as one of the top 5 leading innovative companies in life sciences in Scotland.
In a recent blog by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, Synpromics is listed as one of 7 prominent players in the UK’s thriving synthetic biology sector .
David Venables, CEO of Synpromics, will sit on the panel ‘Gene Therapy: Building the gene medicine pipeline through next generation technologies’ on the 4th October at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California.